ReviewHaemophilia : the official journal of the World Federation of Hemophilia
Considerations for the Use of AAV-based Gene Therapy in HIV-Positive Individuals With Haemophilia.
Review in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThere is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions. Adeno-associated virus (AAV)-based gene therapy restores endogenous factor expression and offers an alternative to routine prophylaxis for haemophilia that individuals living with haemophilia and HIV infection may find uniquely appealing to alleviate the treatment burden for at least one of their chronic conditions.
aimThe aim of this article is to provide guidance on clinical practice to health care professionals considering gene therapy as a treatment option for individuals with haemophilia and HIV.
methodsWe compile available safety and efficacy evidence from participants living with HIV who participated in gene therapy trials for haemophilia. Then, based on this evidence, we provide several HIV-specific considerations for individuals with haemophilia and HIV comorbidity.
conclusionAs part of a shared decision-making approach, it is important to not only evaluate if gene therapy is appropriate but also to offer recommendations on what to expect when navigating the treatment journey. The available evidence to date indicates modern antiretroviral therapy (ART) regimens may not cause complications when combined with AAV-based gene therapies. Accordingly, HIV infection should not be considered a general contraindication for gene therapy to restore factor expression in haemophilia. However, a careful consideration of the individual's life context, especially hepatotoxic drug effects or interactions, is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.